Compass Therapeutics (NASDAQ:CMPX) Now Covered by Lifesci Capital

Key Points

• Lifesci Capital has initiated coverage on Compass Therapeutics (NASDAQ:CMPX), assigning an "outperform" rating and a price target of $10.00, indicating a potential upside of 170.27% from the current price.
• The stock has garnered mixed ratings, with one analyst giving it a Strong Buy, nine Buy, and one Sell, resulting in a consensus rating of "Moderate Buy" and a consensus price target of $13.10.
• Compass Therapeutics reported a loss of ($0.14) earnings per share for its latest quarter, missing the analysts' estimate of ($0.13).

Research analysts at Lifesci Capital initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX - Get Free Report) in a research report issued on Monday,Benzinga reports. The firm set an "outperform" rating and a $10.00 price target on the stock. Lifesci Capital's target price would indicate a potential upside of 170.27% from the stock's current price.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Saturday, September 27th. D. Boral Capital reissued a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, August 12th. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a research note on Tuesday, July 1st. Finally, Guggenheim raised their price target on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $13.10.

Compass Therapeutics Trading Up 6.6%

Shares of CMPX stock opened at $3.70 on Monday. Compass Therapeutics has a 12 month low of $1.27 and a 12 month high of $4.08. The stock has a market cap of $511.65 million, a P/E ratio of -8.22 and a beta of 1.48. The company has a 50 day simple moving average of $3.27 and a two-hundred day simple moving average of $2.60.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CMPX. Creative Planning purchased a new stake in shares of Compass Therapeutics in the 2nd quarter valued at $30,000. Strs Ohio acquired a new position in Compass Therapeutics during the first quarter valued at $34,000. Squarepoint Ops LLC purchased a new stake in Compass Therapeutics in the fourth quarter valued at $35,000. Birchview Capital LP purchased a new stake in Compass Therapeutics in the first quarter valued at $46,000. Finally, Walleye Trading LLC purchased a new position in shares of Compass Therapeutics during the 1st quarter valued at about $48,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.